{"denoms":[{"counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"26"}],"units":"Participants"}],"groups":[{"description":"* Metastatic platinum-resistant or refractory OvC previously treated with ≥1 line of prior platinum-containing therapy\n* Galinpepimut-S + Montanide + GM-CSF + pembrolizumab","id":"BG000","title":"Ovarian Cancer (OvC)"},{"description":"Metastatic CRC previously treated with ≥ 2 lines of prior systematic chemotherapies Galinpepimut-S + Montanide + GM-CSF + pembrolizumab","id":"BG001","title":"Colorectal (CRC)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.9","value":"63.8"},{"groupId":"BG001","spread":"0","value":"40"},{"groupId":"BG002","spread":"7.9","value":"63.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"50","upperLimit":"76","value":"65"},{"groupId":"BG001","lowerLimit":"40","upperLimit":"40","value":"40"},{"groupId":"BG002","lowerLimit":"50","upperLimit":"76","value":"65"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"26"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"15"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"19"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"48","upperLimit":"94","value":"61.7"},{"groupId":"BG001","lowerLimit":"69.5","upperLimit":"69.5","value":"69.5"},{"groupId":"BG002","lowerLimit":"48","upperLimit":"94","value":"61.7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Weight","unitOfMeasure":"kg"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"150","upperLimit":"172","value":"160"},{"groupId":"BG001","lowerLimit":"169","upperLimit":"169","value":"169"},{"groupId":"BG002","lowerLimit":"150","upperLimit":"172","value":"160"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Height","unitOfMeasure":"cm"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18.6","upperLimit":"34.2","value":"25.03"},{"groupId":"BG001","lowerLimit":"24.3","upperLimit":"24.3","value":"24.3"},{"groupId":"BG002","lowerLimit":"18.6","upperLimit":"34.2","value":"25.03"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"BMI","unitOfMeasure":"kg/m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"18"}],"title":"1"}]}],"description":"ECOG measures patient's functional status. Grade 0 is best, grade 5 worst. Grade 0: Fully active, able to carry on all pre-disease performance without restriction Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities Grade 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours Grade 4: Completely disabled; cannot carry on any self-care; totally confined to bed or chair Grade 5: Dead","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Baseline ECOG","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"13"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"4"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"5"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"}],"title":"Unknown / Not reported"}]}],"description":"The number of anti-cancer therapies that patient received before joining the study.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open.","title":"Lines of prior therapy","unitOfMeasure":"Participants"}],"populationDescription":"Only the Ovarian Cancer (OvC) arm enrolled fully. One subject enrolled in the Colorectal Cancer (CRC) arm but discontinued before efficacy could be assessed. For this reason, this subject was not included in the evaluation for efficacy or safety. The other cohorts did not open."}